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Abstract
Background: Cardiac troponin T is a marker of myocardial injury, especially when measu-
red by means of the high-sensitivity assay (hs-cTnT). The echocardiographic and clinical pre-
dictors of hs-cTnT may be different in ischemic heart failure (IHF) and non-ischemic dilated 
cardiomyopathy (DCM).
Methods: Sixty consecutive patients (19 female, 41 male; mean age 56.3 ± 13.9 years) with 
stable congestive heart failure (33 patient with IHF and 27 patients with DCM), with New 
York Heart Association functional class I–II symptoms, and left ventricular ejection fraction 
< 40% were included.
Results: In patients with IHF peak early mitral inflow velocity (E), E/peak early diastolic 
mitral annular tissue Doppler velocity (Em) lateral, peak systolic mitral annular tissue Doppler 
velocity (Sm) lateral and logBNP were univariate predictors of hs-cTnT above median. But 
only E/Em lateral was an independent predictor of hs-cTnT above median (p = 0.04, HR: 1.2, 
CI: 1–1.4). In patients with DCM; left atrial volume index, male sex, Sm lateral and global 
longitudinal strain (LV-GLS) were included in multivariate model and LV-GLS was detected 
to be an independent predictor for hs-cTnT above median (p < 0.05, HR: 0.7, CI: 0.4–1.0).
Conclusions: While LV-GLS is an independent predictor of hs-cTnT concentrations in  
patients with DCM, E/Em lateral predicted hs-TnT concentrations in patients with IHF.  
(Cardiol J 2014; 21, 1: 67–75)
Key words: high sensitivity troponin T, myocardial mechanics, heart failure, 
echocardiography
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Introduction
Conventional cardiac troponin T (cTnT) assays 
have often been used as a negative or positive 
categorical variable especially to detect acute co-
ronary syndromes [1]. But recently, stepwise rises 
in high sensitivity cardiac troponin T (hs-cTnT) in 
patients with chronic heart failure (HF) have been 
associated with adverse cardiac events [2]. Several 
observations have been made in the general popu-
lation. Hs-cTnT at baseline and during follow-up is 
a powerful predictor of cardiac events in patients 
with HF and in the general population [3, 4].
Natriuretic peptide concentrations have been 
shown to parallel with the clinical severity of 
congestive HF and cardiac dysfunction [5]. B-ty-
pe natriuretic peptide (BNP) may be viewed as 
a marker of ventricular load and hs-cTnT as marker 
of myocardial injury [6].
The risk stratification of patients with left 
ventricular (LV) dysfunction can also be performed 
using echocardiographic parameters such as the 
ejection fraction (EF) and LV global longitudinal 
peak systolic strain (LV-GLS). LV-GLS is highly 
feasible and reliable in patients with LV dysfun-
ction and provides incremental prognostic value 
to EF [7, 8].
The etiology of HF has been studied exten-
sively with regard to prognosis and ischemic HF 
(IHF) was associated with adverse survival in many 
studies [9, 10].
Even if the clinical presentation is similar, 
the pathophysiology and prognosis differ in IHF 
and non-ischemic dilated cardiomyopathy (DCM), 
thus echocardiographic and clinical predictors of 
hs-cTnT concentrations may be different in these 
two distinct entities. Therefore, the purpose of the 
study was to evaluate the correlation between hs-
-cTnT and advanced echocardiographic parameters 
or BNP.
Methods
Study population
Sixty consecutive patients with stable con-
gestive HF (33 patient with IHF and 27 patients 
with DCM) who were admitted to HF outpatient 
clinic were enrolled into the study. The inclusion 
criteria were: New York Heart Association (NYHA) 
functional class I–II HF symptoms, LVEF < 40%, 
confirmed ischemic or non-ischemic HF on cardiac 
catheterisation, normal serum sodium concentra-
tions indicating euvolemic state and stable clinical 
condition with no hospitalization for HF or acute 
ischemic event in the past 6 months. Patients with 
NHYA functional class III–IV symptoms, history of 
involuntary change of weight > 2 kg within 4 weeks 
prior to the outpatient visit, significant renal dys-
function as identified by a creatinine concentration 
> 2 mg/dL, angina or angina equivalent symptoms 
in case of ischemic origin were excluded. Blood 
samples for hs-cTnT measurements were drawn 
just before the echocardiographic examination. 
Patients were treated according to the current HF 
guidelines [11]. The study protocol was approved 
by the institutional ethical committee and written 
informed consent was given by all subjects.
Risk factors
Arterial hypertension was defined as a re-
ported blood pressure of > 140/90 mm Hg or in 
patients receiving anti-hypertensive therapy. Dia-
betes mellitus was defined according to the World 
Health Organization definition as a fasting blood 
glucose concentration of > 126 or > 200 mg/dL 
2 h after an oral glucose tolerance test or in patients 
receiving permanent medical anti-diabetic therapy. 
Hyperlipidemia was defined as blood total choleste-
rol concentrations of > 180 mg/dL or low density 
lipoprotein of > 130 mg/dL or when patients were 
receiving permanent treatment with lipid-lowering 
agents. Impaired renal function was defined as 
glomerular filtration rate (GFR) of < 60 mL/min.
Blood samples
EDTA-treated plasma samples were obtained 
from trial participants simultaneously with echo-
cardiographic examination and centrifuged at room 
temperature. The plasma component was aspira-
ted and frozen at −20°C. Within 3 months after 
collection plasma samples were taken to the labo-
ratory on dry ice for evaluation. Plasma hs-cTnT 
concentrations were measured with hs-cTnT rea-
gents by electrochemiluminescence immunoassay 
(ECLIA) with Elecsys Troponin T-High Sensitive 
Immunoassay (Roche Diagnostics Ltd.), with an 
analytical measurement range of 0.003–10 ng/mL. 
The value at the 99th percentile cut-off from 
a healthy reference population was 0.014 ng/mL. 
Interassay coefficient of variation according to the 
manufacturer was 3.1% at 0.024 ng/mL and 1.3% 
at 0.300 ng/mL [12]. 
The quantitative determination of BNP in 
plasma was done by immune fluorescence method 
using the ADVIA Centaur System (Bayer Diagno-
stics, Tarrytown, NY, USA). GFR was estimated 
by age, weight, creatinine, and sex using the 
Cockcroft-Gault formula. Hemoglobin, sodium, 
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potassium and blood urea nitrogen concentrations 
belonging to the same outpatient clinic visit were 
also obtained from our local laboratory.
Transthoracic echocardiographic  
examination
All echocardiographic examinations and tissue 
Doppler imaging (TDI) were performed using 2– 
–4 MHz phased array transducer (Vivid 7 pro; GE, 
Horten, Norway) by a cardiologist and recorded 
for offline analysis (Echopac PC, GE). Individuals 
were instructed to hold their breath, and images 
were coupled with electrocardiographic recordings. 
Measurements were done offline later by a single 
investigator with more than four years’ experience, 
who was blinded to the clinical and hs-cTnT data. 
M-mode measurements were performed according 
to the criteria of the American Society of Echocar-
diography. Three consecutive cycles were averaged 
for every parameter and 5 cycles for atrial fibrilla-
tion. Left atrial (LA) dimension and LV end-systolic 
and end-diastolic diameters were measured. LVEF 
was estimated by Simpson’s rule. Interventricu-
lar septum thickness (IVST) and posterior wall 
thickness (PWT) were measured, and LV mass 
(LVM) was estimated. For determination of LVM, 
the Devereux formula was used: LVM [g] = 
= 0.8 × (1.04 × [(LVID + PWT + IVST)³ – 
– LVID³]) + 0.6; (LVID indicates LV internal di-
mension). LVM index (LVMI) was calculated by 
dividing LVM by body surface area [13].
Left atrial volume (LAV) was calculated at 
end systole of the left ventricle by measuring the 
LA area in the apical 4- (A1) and 2-chamber (A2) 
views and measuring the LA distance from apical 
4 chamber view beginning from the center of mitral 
annulus. A1 × A2 × 0.85/LA distance formula was 
used to calculate LAV. LA volume index (LAVI) was 
calculated by dividing LAV by body surface area 
and expressed in mL per m² [14].
Transmitral pulsed-wave Doppler velocities 
were recorded from the apical 4-chamber view 
with the Doppler sample placed between the tips 
of the mitral leaflets. Early (E) and late (A) wave 
velocities, E/A ratio, E deceleration time were 
measured from the mitral inflow profile. The same 
echocardiography machine was used to acquire TDI 
data at high frame rates. The Nyquist limit was set 
at 15–20 cm/s, and minimal optimal gain was used. 
The myocardial systolic (Sm), early diastolic (Em), 
and late diastolic (Am) velocities were obtained 
at the septal and lateral mitral annulus by placing 
a sample volume. The E/Em ratio was subsequ-
ently calculated for septal and lateral measure-
ments. Mitral regurgitation was characterized as 
follows: mild (regurgitation orifice area £ 0.2 cm²), 
moderate (0.2–0.39 cm²) and severe (≥ 0.4 cm²). 
Intraobserver variability in measurement ranged 
from 4% for tissue Doppler indexes to 8% for 
transmitral indexes.
LV global longitudinal strain measurements
The LV-GLS measurements were performed 
offline using dedicated software (Echopac PC) and 
2-dimensional speckle tracking imaging method. 
Special care was taken to ensure frame rates of be-
tween 50 and 90 frames per second in all patients. 
One cardiac cycle was acquired from apical 4-cham-
ber, 2-chamber and long axis views for LV-GLS; 
the endocardial border was traced manually in the 
end-diastolic frame. In segments with poor tracking 
(assessed subjectively) endocardial borders were 
readjusted until better tracking was achieved. If 
this was unattainable, that segment was excluded. 
Graphical displays of deformation parameters for 
each segment were then generated automatically 
and were used for measurement of LV-GLS values 
(Fig. 1). Each apical view was divided into 6 seg-
ments by the software. Peak systolic longitudinal 
strain was calculated by averaging the peak systo-
lic values of 18 segments, derived from 3 apical 
views. Peak global strain was defined as the peak 
negative systolic value on the strain curve during 
the entire cardiac cycle. We obtained LV-GLS only 
in the case of adequate tracking quality > 5 of the 
6 segments per view. Any view in which 2 or more 
segments could not be tracked was not included in 
the analysis, and the remaining apical views were 
averaged to calculate LV-GLS. Reproducibility in 
the LV-GLS measurement was 0.59 ± 0.70% and 
93% (1021/1098) of the myocardial segments were 
adequately tracked.
Statistical analysis
Continuous variables are summarized as mean 
± SD if normally distributed, and as median if 
distributed not normally. Also, if plasma hs-cTnT 
and BNP concentrations were non- normally distri-
buted, we converted these data to log format for 
various comparisons. Normally distributed variab-
les were compared using t-test and non-normally 
distributed variables were analyzed with Mann-
-Whitney U test. 
Non-parametric correlations between hs-
-cTnT concentrations and clinical variables were 
determined by Spearman’s rho test. The patients 
were grouped according to median hs-cTnT va-
lue and binary logistic regression analysis was 
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Figure 1. The endocardial border was traced manually in the end-diastolic frame. Graphical displays of deformation 
parameters for each segment were then generated automatically in apical 4 (A), 3 and 2 chamber views. Finally, left 
ventricular average global longitudinal strain for 18 segments (GLPS_Avg) was presented in bull’s eye (B) scheme.
A
B
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performed to examine the relationship between 
hs-cTnT and other variables. Variables which sho-
wed significant correlation with hs-cTnT groups 
by univariate binary logistic regression analyses 
were tested with multiple regression analysis. 
Independent predictors of hs-cTnT above median 
were determined for both IHF and DCM groups. 
Reproducibility of echocardiographic parameters 
was assessed between measurements by coeffi-
cients of variation (standard deviation of differen-
ces between the repeated measurements divided 
by the mean value and expressed as percent). 
The intraobserver variability was calculated from 
25 randomly selected subjects. Statistical analyses 
were performed with SPSS for Windows, version 
20.0. P-values less than 0.05 were considered sta-
tistically significant.
Results
Patient characteristics
Clinical characteristics of patents are listed in 
Table 1. The patient population consisted of 19 fe-
male, 41 male patients aged 56.3 ± 13.9 years. Thir-
ty-three patients presented with IHF and 27 with 
DCM. Hs-cTnT was detectable (> 0.003 ng/mL) 
in all patients and 20 (30%) patients had hs-cTnT 
concentrations of > 0.014 ng/mL. Hs-cTnT con-
centrations were higher in males when log hs-cTnT 
values were compared [–1.9 ± 0.26 for males 
(n = 41) vs. –2.2 ± 0.24 for females (n = 19); 
p < 0.001]. Median values of hs-cTnT were 
0.006 ng/mL for females and 0.011 ng/mL for males. 
Mean GFR was 88.8 ± 29.1 mL/min for the whole 
cohort, 11 (18%) patients had GFR < 60 mL/min 
and there was no significant difference between 
GFR values in patients with IHF and DCM. Hs-
-cTnT concentrations, EF, as well as aortic annulus 
diameters were higher in patients with IHF. How-
ever, LAVI was detected to be higher in patients 
with DCM. BNP values were not different statisti-
cally when compared for IHF and DCM (Table 2).
Correlations of hs-cTnT with  
clinical variables and BNP
When non-parametric correlations were analy-
zed hs-cTnT was found to be positively correlated 
with age, LV end-diastolic diameter (LVEDD), 
diameter of the aortic annulus, right ventricular 
and right atrial dimensions, E/Em lateral, BNP, 
and creatinine. It was also negatively correlated 
with Sm lateral and LV-GLS. However, there was 
no correlation between LWMI, GFR, LAVI and 
hs-cTnT (Table 3).
Table 1. Baseline characteristics of the study  
population.
Clinical features
Age [years] 56.3 ± 14
Sex (males) 41 (68%)
Etiology (IHF) 33 (55%)
Atrial fibrillation 13 (22%)
Renal failure 10 (18%)
Diabetes mellitus 13 (22%)
Hypertension 37 (62%)
Hyperlipidemia 17 (29%)
Smoking 13 (22%)
Pharmacologic treatment
Beta-blocker 57 (95%)
ACEI/ARB 49 (82%)
Furosemide 39 (65%)
Spironolactone 46 (77%)
Digoxin 9 (15%)
Acetylsalicylic acid 48 (80%)
OAD 11 (18%)
Insulin 4 (7%)
Statin 15 (25%)
Nitrates 8 (13%)
Echocardiographic parameters
Mitral regurgitation:
None 4 (6.7%)
Mild 34 (56.7%)
Moderate 11 (18.3%)
Severe 11 (18.3%)
LVEDD [cm] 6.7 ± 0.7
LVESD [cm] 5.5 ± 0.7 
EF [%] 30.8 ± 6.5
GLS [%] –7 ± 2.9
PAPs [mm Hg] 39.2 ± 11.5
LAVI [mL/m2] 42 ± 17
Aortic annulus [cm] 3 ± 0.3
Laboratory findings
Blood urea nitrogen [mg/dL] 39.2 ± 14.7
Potassium [mEq/L] 4.6 ± 0.4
Sodium [mEq/L] 137 ± 3.4
GFR [ml/min] 88.8 ± 29.1
Creatinine [mg/dL] 1.03 ± 0.3
Haemoglobin [g/dL] 13.6 ± 1.5
BNP [pg/mLl] 215 (17–1598)
Hs-cTnT [ng/mL] 0.011 (0.003–0.051)
Data are expressed as numbers (percentage), median (interquartile 
range), or mean ± SD; ACEI — angiotensin converting enzyme 
inhibitors; ARB — angiotensin receptor blockers; BNP — B-type 
natriuretic peptide; EF — ejection fraction; GFR — glomerular filtra-
tion rate; GLS — global longitudinal strain; Hs-cTnT — high sens-
itivity troponin T; IHF — ischemic heart failure; LAVI — left atrial 
volume index; LVEDD — left ventricular end-diastolic diameter; 
LVESD — left ventricular end-systolic diameter; OAD — oral anti-
diabetic agents; PAPs — systolic pulmonary artery pressure
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Predictors of hs-cTnT: DCM vs. IHF
The patients were divided into two groups 
according to hs-cTnT median value; afterwards, 
univariate and multivariate logistic regression 
analyses were performed to estimate hs-cTnT 
above median.
In patients with IHF mitral E velocity, E/Em 
lateral, Sm lateral and logBNP were univariate pre-
dictors of hs-cTnT above median. But only E/Em 
lateral was an independent predictor of hs-cTnT 
above median (p = 0.04, HR: 1.2, 95% CI 1–1.4). 
However in patient with DCM; LAVI and LV-GLS 
were included in multivariate model and LV-GLS 
was detected to be an independent predictor for 
hs-cTnT above median (p = 0.03, HR 0.7, 95% CI 
0.4–1.0) (Table 4).
Discussion
In the present study we examined the clinical 
and echocardiographic predictors of hs-cTnT in 
patients with IHF vs. DCM. The novel finding 
of our study is that LV-GLS was an independent 
predictor of hs-cTnT in patients with DCM, but it 
was not even a univarite predictor in patients with 
IHF. Additionally, E/Em lateral was an independent 
predictor of hs-cTnT concentrations in patients 
with IHF. 
Table 2. Clinical and laboratory findings of patients with heart failure grouped according to etiology.
Variable Ischemic heart failure (n = 33) Dilated cardiomyopathy (n = 27) P
Clinical and key laboratory findings 
Age [years] 59.0 ± 9.5 53.0 ± 17.5 0.093
Hs-cTnT [ng/mL] 0.014 (0.004–0.051) 0.008 (0.003–0.029) 0.018*
BNP [pg/mL] 198 (19.4–1598) 249.4 (17.2–1540) 0.345
Log hs-cTnT –1.9 ± 0.3 –2.1 ± 0.3 0.015*
Log BNP 2.2 ± 0.3 2.3 ± 0.4 0.290
Echocardiographic parameters 
GLS [%] –6.8 ± 3.0 –7.2 ± 3.0 0.640
EF [%] 33 ± 6 29 ± 7 0.015*
LWMI [g/m2] 180 (39.7–312.5) 166 (99.6–310) 0.694
LVEDD [cm] 6.8 ± 0.6 6.6 ± 0.7 0.285
LVESD [cm] 5.5 ± 0.7 5.6 ± 0.7 0.699
Aortic annulus [cm] 3.0 ± 0.3 2.9 ± 0.3 0.017*
LAVI [ml/m2] 38 ± 15.2 47 ± 18.0 0.039*
E mitral [m/s] 0.86 ± 0.31 0.92 ± 0.31 0.433
Em septum [m/s] 0.053 ± 0.016 0.056 ± 0.016 0.388
Em lateral [m/s] 0.071 ± 0.025 0.075 ± 0.037 0.656
E/Em septum 16.7 (6.7–43.3) 14.8 (10–47.5) 0.882
E/Em lateral 11 (5.4–29.2) 11.5 (5–63.3) 0.567
RVEDD [cm] 3.4 ± 0.5 3.2 ± 0.5 0.218
RA [cm] 3.6 ± 0.6 3.4 ± 0.5 0.108
PAPs [mm Hg] 38.9 ± 13.3 39.5 ± 9.0 0.858
TAPSE [cm] 1.7 ± 0.3 1.7 ± 0.5 0.939
Other laboratory findings
GFR [mL/min] 90.0 ± 30.1 87.3 ± 27.3 0.727
Sodium [mEq/L] 137 ± 3.8 137 ± 3 0.712
Potassium [mEq/L] 4.6 ± 0.5 4.6 ± 0.4 0.613
BUN [mg/dL] 41.8 ± 13.9 36.5 ± 15.3 0.161
Hemoglobin [g/dL] 13.8 ± 1.4 13.5 ± 1.7 0.501
Data are expressed as mean ± SD or median (interquartile range); *p < 0.05; BNP — B-type natriuretic peptide; BUN — blood urea nitrogen; 
E mitral — peak early diastolic inflow velocity; EF — ejection fraction; Em — peak early diastolic tissue Doppler velocity; GFR — glomerular 
filtration rate; GLS — global longitudinal strain; Hs-cTnT — high sensitivity troponin T; LAVI — left atrial volume index; LVEDD — left ventri-
cular end-diastolic diameter; LVESD — left ventricular end-systolic diameter; LWMI — left ventricular mass index; PAPs — systolic pulmonary 
artery pressure; RA — right atrium; RVEDD — right ventricular end diastolic diameter; TAPSE — tricuspid annular plane systolic excursion
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Several hypotheses, including subendocardial 
ischemia due to a mismatch between myocardial 
oxygen supply and demand, have been proposed as 
explanation for increased concentrations of cTnT 
in HF, but the mechanisms by which these features 
cause increase in troponin concentrations in the 
absence of an acute coronary syndrome remain 
uncertain. Higher troponin concentrations were 
observed in patients with HF of ischemic etiology, 
yet, consistent with our findings, elevated troponin 
concentrations were reported also in patients with 
non-ischemic HF [9, 10]. An elevation in cardiac 
troponins can indicate the presence of myocyte 
injury or death. The pathophysiological factors that 
are thought to be responsible for ongoing myocyte 
injury or cell death include excessive adrenergic 
stimulation through renin–angiotensin–aldostero-
ne or endothelin signalling pathways, abnormalities 
in calcium handling, inflammatory cytokines, nitric 
oxide, and oxidative or mechanical stress [15].
However, the elevations of cTnT were de-
tectable only in a small fraction of patients with 
stable chronic HF because previous studies used 
conventional troponin T assays for the lower de-
tection limit of 0.01 ng/mL. Recently, the highly 
sensitive assay for cTnT has been developed and 
made it possible to measure concentrations about 
10-fold lower than the lower detection limit of the 
previous conventional assay [12]. Thanks to the 
highly sensitive assay, circulating cTnT has been 
detected in a large population of patients with HF, 
and it provided prognostic information about pre-
viously undetectable concentrations regardless of 
their etiology [2, 16]. The prognostic significance of 
hs-cTnT assay was reported a continuous variable 
Table 3. Non-parametric correlations of hs-cTnT 
with other clinical variables.
Variable r p
Age 0.28 0.033*
LVEDD 0.26 0.044*
LVESD 0.21 0.11
EF –0.024 0.85
PW 0.24 0.07
LA 0.17 0.2
Aortic annulus 0.37 0.004*
LAVI –0.033 0.8
E mitral 0.15 0.26
Em septal –0.16 0.23
Em lateral –0.16 0.21
E/Em septal 0.16 0.21
E/Em lateral 0.26 0.043*
Sm lateral –0.41 0.001*
Sm septum –0.1 0.47
RVEDD 0.36 0.004*
RA 0.26 0.043*
GLS –0.32 0.013*
LWMI 0.11 0.39
BNP 0.28 0.029*
GFR –0.15 0.25
Creatinine 0.34 0.009*
Sodium –0.13 0.34
Potassium 0.17 0.18
Hemoglobin –0.003 0.98
*p < 0.05; BNP — B-type natriuretic peptide; E mitral — peak early 
diastolic inflow velocity; EF — ejection fraction; Em — peak early 
diastolic tissue Doppler velocity; GFR — glomerular filtration rate; 
GLS — global longitudinal strain; Hs-cTnT — high sensitivity tro-
ponin T; LA — left atrium; LAVI — left atrial volume index; LVEDD 
— left ventricular end diastolic diameter; LVESD — left ventricular 
end-systolic diameter; LWMI — left ventricular mass index; PW — 
posterior wall; RA — right atrium; RVEDD — right ventricular end-
-diastolic diameter; Sm — peak systolic tissue Doppler velocity
Table 4. Univariate and multivariate relations for prediction of hs-cTnT concentrations.
Univariate Multivariate
HR 95% CI P HR  95% CI P
Ischemic heart failure
E mitral 14 1–194 0.043 NS
E/Em septal 1.1 1–1.2 0.061 NS
E/Em lateral 1.2 1–1.4 0.040 1.2 1–1.4 0.04
Sm lateral 1.5 1–1.9 0.040 NS 
Log BNP 8 1–62.8 0.049 NS
Non-ischemic cardiomyopathy
Male sex 0.25 0.05–1.2 0.088 NS
LAVI 0.9 0.9–1 0.045 NS
Sm lateral 0.95 0.9–1 0.068 NS
GLS 0.7 0.4–1 0.030 0.7 0.4–1 0.03
BNP — B-type natriuretic peptide; CI — confidence interval; E mitral — peak early diastolic inflow velocity; Em — peak early diastolic tissue 
Doppler velocity; GLS — global longitudinal strain; HR — hazard ratio; Hs-cTnT — high sensitivity troponin T; LAVI — left atrial volume index; 
NS — not significant; Sm — peak systolic tissue Doppler velocity
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in patients with chronic HF, in contrast to the con-
ventional cTnT assay, often described as a positive 
or negative categorical variable [2]. Furthermore, 
Miller et al. [17, 18] reported that a decrease in 
cTnT concentrations to normal values was asso-
ciated with a decrease in risks of death or cardiac 
transplantation, whereas a normalization of BNP 
concentrations did not change these risks. Even 
small elevations of cTnT concentrations might be 
an indication for more aggressive treatment.
Previously, hs-cTnT > 0.003 ng/mL was as-
sociated with male sex, older age, history of HF, 
lower renal function, and a greater LVM [19]. Male 
patients in our study population also had higher 
hs-cTnT concentrations than females and their 
age was correlated with hs-cTnT concentrations 
consistent with these findings, but GFR and LWMI 
were not related to hs-cTnT concentrations. The 
reason for this may be the exclusion of patients 
with creatinine concentrations of > 2 mg/dL 
and relatively preserved renal function of our 
study population. In the mentioned study electro-
cardiographic LV hypertrophy was an independent 
predictor of hs-cTnT, although we evaluated echo-
cardiographic LV hypertrophy.
E/Em lateral was an independent predictor 
of higher hs-cTnT concentrations in patients 
with IHF. Since E/Em lateral predicts pulmonary 
capillary wedge pressure and is less affected from 
coronary artery disease than E/Em septal, worse-
ning subendocardial demand-supply relationship 
as a result of diastolic dysfunction may be the 
dominating pathophysiologic mechanism respon-
sible for cTnT release. Recently, Eggers et al. [20] 
examined 103 stable patients with LV dysfunction 
and found that patients with higher hs-cTnT 
(> 13.5 ng/L) had higher pulmonary capillary 
wedge pressure, mean right atrial pressure, mean 
pulmonary artery pressure, and pulmonary vascu-
lar resistance, but lower cardiac index than patients 
with lower hs-cTnT (£ 13.5 ng/L).
Our study showed that in patients with DCM 
LV-GLS was an independent predictor of hs-cTnT 
concentrations. LV mechanics is a complex, coor-
dinated action involving longitudinal contraction, 
circumferential shortening, and radial thickening. 
Additionally, many studies have shown that mea-
surement of LV longitudinal motion by the mitral 
annular excursion or velocities has been a good 
index of LV function and also a predictor of progno-
sis in HF [21–25]. Recently decreased longitudinal 
mechanics (LV-GLS) was associated with increased 
cardiac events of both ischemic and non-ischemic 
HF during 5 years of follow-up. Moreover, LV-GLS 
was reported to have significant incremental value 
over conventional clinical and echocardiographic 
parameters, including longitudinal velocity [7]. 
We speculate that LV-GLS may be a more valuable 
prognostic marker in DCM rather than IHF.
Limitations of the study
The major limitation of the present study is 
the relatively low number of patients included. 
Therefore, our results are only hypothesis gene-
rating and require confirmation in larger studies. 
The hs-cTnT concentrations were measured only 
once at presentation to outpatient clinic, so acute 
coronary syndrome as a cause of hs-cTnT release 
might be overlooked. Besides, we did not perform 
invasive testing or long term rhythm Holter follow-
-up. It is therefore convincible that to certain extent 
clinically undetected variation of phenotype such as 
intermittent change in rhythm or change of loading 
conditions might confound the findings.
Conclusions
In contrary to acute coronary syndromes, an 
objective risk-stratification process for the eva-
luation of patients with HF is lacking. Early risk 
stratification may help identify patients who are 
likely to receive the greatest benefit from early 
intensive therapy. Since DCM and IHF are distinct 
clinical entities both presenting with HF, it may 
be reasonable to use different risk stratification 
measures.
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